Entera Bio names ex-Gilead and Amgen executive Laura Hamill to board
Hamill, who led Gilead's worldwide commercial operations, joins Entera's board effective December 1, 2026, replacing departing director Yonatan Malca.
Entera Bio Ltd. (NASDAQ: ENTX) announced on October 6, 2026 the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026.1 She succeeds Yonatan Malca, who is stepping down from the Board.1
Hamill, age 62, is a biopharmaceutical executive with more than 35 years of commercial leadership experience.1 She most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc.1 In that role she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue and oversaw the transformation of the company's global commercial operations.1 Before Gilead, she spent nearly two decades at Amgen Inc. in roles of increasing scope, including senior leadership positions overseeing U.S. commercial business operations and Amgen's Intercontinental Region.1
Hamill currently sits on the boards of "Jazz Pharmaceuticals plc," "BB Biotech AG," and "Fate Therapeutics, Inc.," and previously served on the boards of Acceleron Pharma Inc., Pardes Biosciences, and Y-mAbs Therapeutics, Inc., according to the filing.
The company said Hamill has also been appointed to serve as a member of both the audit committee and corporate governance and nomination committee of the Board, in each case, effective December 1, 2026.1 The filing states there are no arrangements or understandings between Hamill and any other person pursuant to which she was appointed as a director of the Company,1 and the board found her to meet SEC and Nasdaq independence standards.
Regarding Malca's exit, the filing states his departure from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.1
Entera describes itself as a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care.1 Its lead candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic once-daily tablet for osteoporosis.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.